Policy & Regulation
Orig3n Inc acquires Interleukin Genetics CLIA laboratory and remaining assets for undisclosed value
23 November 2017 -

Biotech company Orig3n Inc revealed on Wednesday the completion of the acquisition of Interleukin Genetics CLIA laboratory and their remaining assets for an undisclosed amount.

Upon closing, Interleukin's technology will become a core component of Orig3n's DNA test business to empower more people to take charge of their health through genetic insights.

Orig3n acquires Interleukin Genetics' CLIA-Certified Genetics Laboratory in Waltham, Massachusetts. The automated genotyping lab is fully-licensed for testing in all 50 US states and is capable of processing over one million samples per year. Its state-of-the-art technology and its HIPAA and HITECH compliance brings its ILUSTRA Inflammation Management Programme and its Inherent Health genetic tests for nutritional needs, weight management, heart health and bone health.

Via the acquisition, all personalised genetic tests will be consolidated under the Orig3n brand.

Under the terms of the agreement, Orig3n's regenerative medicine research lab will remain in Boston's Innovation District and the genetic testing will be consolidated to Interleukin Genetics' CLIA laboratory.

In conjunction with the acquisition, Rene Oda, director of Technology at Interleukin Genetics, will join Orig3n as the director of Product Management and Dr Lynn Doucette-Stamm, joins Orig3n as senior vice president of development and clinical operations.